Customer Outcomes & Value Experiencing A New Monitoring Technology

LifeScan Scotland Ltd170 enrolled

Overview

To investigate whether novel insight features in new Blood Glucose Monitoring System (BGMs) can improve glycemic control.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

170

Conditions

Diabetes Mellitus

Interventions

LifeScan's new BGMSDEVICE

LifeScan new Blood Glucose Monitoring System (BGMS)

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria Summary: * Diagnosed with Type 1 diabetes mellitus or Type 2 diabetes mellitus for ≥ 3 month prior to screening * Currently performing self-monitoring of blood glucose (SMBG) at home for diabetes management decisions * Willingness to notify the study staff if they become pregnant during the study * Willing to sign an informed consent Exclusion Criteria Summary: * Currently using a continuous or flash glucose monitoring * Currently pregnant or planning pregnancy within duration of study or breast feeding; subjects who become pregnant during the study will be withdrawn. * Conflict of Interest

Locations (2)

Royal Infirmary of Edinburgh

Edinburgh, Lothian, United Kingdom

RECRUITING

Highland Diabetes Institute

Inverness, United Kingdom

RECRUITING

Outcomes

Primary Outcomes

A1c change from baseline after 12 weeks

A1c change from baseline after 12 weeks in subjects using new BGMS compared to subjects' pre-study glycemic control

Time frame: 12 weeks

Central Contacts

Mike Grady

CONTACT

01463 721000 MGRADY@lifescan.com

Kirsty Macleod

CONTACT

kmacleod@lifescan.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.